このエントリーをはてなブックマークに追加
ID 52345
FullText URL
Author
Kagawa, Hidetoshi
Hiromasa, Tsutomu
Hara, Takayuki
Takaki, Ayako
Yamanaka, Ryutaro
Abstract
Conventional cyclophosphamide-based treatment regimens for lupus nephritis (LN) are still not considered to be optimal. The aim of this study was to evaluate the efficacy and safety of mizoribine, tacrolimus, and corticosteroid combination therapy for LN. We retrospectively evaluated a combination treatment of mizoribine and tacrolimus with corticosteroids as induction therapy in eight newly diagnosed systemic lupus erythematosus (SLE) patients with biopsy-proven LN. All patients were women, and their mean [standard deviation (SD)] age was 48.5 (20) years. All patients (100 %) had positive anti-double-stranded DNA (anti-dsDNA) antibody titers, and four (50.0 %) were nephrotic. Mean (SD) serum creatinine and daily proteinuria levels were 0.72 (0.4) mg/dl (range 0.33-1.55 mg/dl) and 4.56 (2.8) g (range 0.77-8.2 g), respectively. By month 2, significant improvements in the anti-dsDNA antibody titers, levels of proteinuria, serum albumin, and C3, and SLE disease activity index score were observed. By month 6, seven patients (87.5 %) were in complete remission, with normalized levels of both proteinuria and serum creatinine. This pilot study suggests that mizoribine and tacrolimus treatment with corticosteroids is well tolerated and may prove to be an optimal alternative remission-inducing regimen for LN.
Keywords
Induction therapy
Lupus nephritis
Mizoribine
Multitarget therapy
Systemic lupus erythematosus
Tacrolimus
Note
The original publication is available at www.springerlink.com
Published Date
2012-10
Publication Title
Clinical and Experimental Nephrology
Volume
volume16
Issue
issue5
Publisher
Springer
Start Page
760
End Page
766
ISSN
1342-1751
Content Type
Journal Article
Related Url
http://ousar.lib.okayama-u.ac.jp/metadata/52252
language
英語
File Version
author
Refereed
True
DOI
Web of Sience KeyUT